Hybio Pharmaceutical Co., Ltd

Short Term Long Term Short Term Comparison Long Term Comparison
  • 300199
  • 1d-0.99%
  • 1w-1.52%
  • 1m-19.32%
  • 1y1.01%
ATH
  • ATH Price$49.32
  • ATH Date2015-06-10
  • % since ATH-77.74%
  • % to ATH349.17%
ATL
  • ATL Price$2.85
  • ATL Date2012-12-04
  • % from ATL284.71%
  • Last Low Price$4.34
  • Last Low Date2021-04-12
  • % From Last Low153.00%
IPO
  • IPO Price$30.33
  • % Current ROI USD-63.80%
  • ATH Price$49.32
  • % ROI ATH 172,799.48%
[addtoany]

Graph takes few seconds to load...

[financial_chart symbol="300199"]

Key Data [addtoany]

Current price $10.98
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Today's High/Low $11.18/$10.96
Volume 12,302,035.00
Previous Close $11.09
52 Week High/Low $20.88/$8.66
Market Cap 9,697,985,536.00
P/E Ratio 0
Forward P/E 1 Yr. $0.00
Earnings Per Share(EPS) $0.08
Annualized Dividend $0
$10.98
[addtoany]

Hybio Pharmaceutical Co., Ltd., a peptide pharmaceutical company, engages in the research and development, manufacture, and sale of polypeptide drugs in the People’s Republic of China and internationally.
Its peptide finished dosage products include digestive system agents, immune modulators, PTH and Ca metabolic modulators, hormone and endocrine modulators, FD for circulatory and blood systems, antiviral agents, and hemostatic products.
The company also provides custom and GMP peptides; and a range of peptide APIs. Hybio Pharmaceutical Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the People’s Republic of China.

Annual Data | Millions of US $ except per share data
Cash on hand
Receivables
Inventory
Pre-Paid Expenses
Other Current Assets
Total Current Assets
Property, Plant, And Equipment
Long-Term Investments
Goodwill And Intangible Assets
Other Long-Term Assets
Total Long-Term Assets
Total Assets
Total Current Liabilities
Long Term Debt
Other Non-Current Liabilities
Total Long Term Liabilities
Total Liabilities
Common Stock Net
Retained Earnings (Accumulated Deficit)
Comprehensive Income
Other Share Holders Equity
Share Holder Equity
Total Liabilities And Share Holders Equity